Procalcitonin (PCT) is a 116-amino-acid polypeptide prohormone of , primarily produced in the C-cells of the under normal physiological conditions [1]. However, during systemic bacterial infections, PCT is widely synthesized by extra-thyroidal tissues—including the liver, lungs, and adipocytes—in response to bacterial endotoxins such as and pro-inflammatory cytokines like and [2]. This marked elevation makes PCT a highly specific for severe bacterial infections, particularly in diagnosing and monitoring and differentiating bacterial from viral etiologies in acute respiratory infections [3]. Unlike , which increases in various inflammatory states, PCT demonstrates greater specificity for bacterial sepsis, with levels typically remaining low in viral infections and non-infectious inflammation [4]. Clinically, PCT is used to guide antibiotic initiation and duration in settings such as , , and , supporting antimicrobial stewardship by reducing unnecessary antibiotic exposure [5]. Its rapid kinetics—detectable within 3–6 hours post-infection, peaking at 12–24 hours, and with a half-life of approximately 24–29 hours—enable timely clinical decisions [6]. Despite its utility, PCT levels can be elevated in non-infectious conditions such as major surgery, severe trauma, burns, and certain cancers, necessitating careful interpretation within the full clinical context [7]. Standardized immunoassay techniques, including and , allow for reliable quantification, though inter-laboratory variability and potential interference from heterophilic antibodies remain challenges [8]. International guidelines, such as those from the , endorse PCT as an adjunct tool for antibiotic de-escalation, though it should never replace comprehensive clinical evaluation [9].

Definition and Physiological Role

Procalcitonin (PCT) is a 116-amino-acid polypeptide that functions as a prohormone to , a hormone involved in calcium homeostasis [1]. Under normal physiological conditions, PCT is produced in minute quantities primarily by the parafollicular C-cells of the , where it is enzymatically cleaved to generate active calcitonin [2]. However, unlike calcitonin, PCT is not biologically active in this form and serves instead as a crucial biomarker during systemic infections. In healthy individuals, circulating PCT levels are typically below 0.1 µg/L, reflecting its tightly regulated basal expression [4].

Physiological Production and Regulation

The physiological role of PCT extends beyond its function as a precursor molecule. During systemic bacterial, fungal, or parasitic infections, PCT undergoes ectopic production in a wide range of extra-thyroidal tissues, including hepatocytes in the , pneumocytes in the , adipocytes, muscle cells, and immune cells such as [13]. This widespread induction is triggered by bacterial endotoxins—particularly from Gram-negative bacteria—and pro-inflammatory cytokines such as , , and, to a lesser extent, [14]. The activation of , especially TLR-4, initiates a signaling cascade that upregulates the CALC-1 gene, leading to the transcription and release of PCT into the bloodstream [13].

Role as a Biomarker of Systemic Infection

PCT plays a central role as a biological marker of systemic bacterial infection, offering several advantages over other inflammatory markers. Its rapid kinetics allow for early detection: levels become detectable within 3–4 hours of infection onset, peak between 12 and 24 hours, and have a plasma half-life of approximately 22–29 hours [6]. This predictable clearance, primarily through renal elimination without significant hepatic metabolism, enables reliable monitoring of disease progression and therapeutic response [17].

Clinically, PCT is invaluable for:

  • Early diagnosis of bacterial infections, particularly in critical conditions such as and .
  • Assessment of disease severity, as PCT levels often correlate with the extent of the systemic inflammatory response.
  • Monitoring treatment efficacy, with declining levels indicating a favorable response to .
  • Differentiating bacterial from viral infections, as PCT typically remains low in viral etiologies, aiding in appropriate antimicrobial stewardship [3].

Its stability in serum and the availability of rapid, automated immunoassays—including and —further enhance its utility in clinical settings such as , , and [8]. By guiding decisions on antibiotic initiation and duration, PCT contributes significantly to reducing unnecessary antimicrobial use and combating the global challenge of .

Clinical Applications in Infection Diagnosis

Procalcitonin (PCT) serves as a critical biomarker in the clinical diagnosis and management of infections, particularly in differentiating bacterial from viral etiologies and guiding antimicrobial therapy. Its utility spans multiple medical specialties, including , , , and , where timely and accurate diagnosis is essential for patient outcomes. The specificity of PCT for systemic bacterial infections—especially in the context of and severe respiratory infections—makes it a cornerstone in modern management and programs.

Diagnosis of Sepsis and Severe Bacterial Infections

PCT is a key diagnostic tool for identifying systemic bacterial infections, particularly sepsis and septic shock. It rises rapidly within 3–6 hours of infection onset, peaks at 12–24 hours, and correlates with the severity of the inflammatory response [6]. Unlike general markers of inflammation, PCT demonstrates high specificity for bacterial sepsis, making it valuable in early detection and risk stratification. In critically ill patients presenting with signs of systemic inflammation, a PCT level > 0.5 ng/mL strongly suggests a bacterial etiology, while levels > 2.0 ng/mL are highly suggestive of severe sepsis or septic shock [21]. This allows clinicians to initiate appropriate promptly, improving survival rates in time-sensitive conditions.

Differentiation Between Bacterial and Viral Infections

One of the most impactful applications of PCT is its ability to distinguish bacterial from viral infections, particularly in acute respiratory syndromes. In viral infections, PCT levels typically remain low or only mildly elevated, whereas bacterial infections trigger a pronounced increase due to stimulation by bacterial endotoxins like and pro-inflammatory cytokines such as and [2]. This distinction is crucial in settings like emergency departments and outpatient clinics, where overuse of antibiotics for viral illnesses contributes to global . For instance, in patients with suspected lower respiratory tract infections, a PCT level < 0.1 µg/L indicates a low probability of bacterial infection, supporting the decision to withhold antibiotics [3]. This evidence-based approach reduces unnecessary antibiotic exposure without compromising patient safety.

Management of Respiratory Infections

In pneumology, PCT is extensively used in managing acute respiratory infections such as community-acquired pneumonia (CAP) and acute exacerbations of chronic obstructive pulmonary disease (COPD). For CAP, a PCT level > 0.25 ng/mL supports a bacterial cause and justifies antibiotic initiation, while levels < 0.1 ng/mL make bacterial infection unlikely [24]. Similarly, in COPD exacerbations, PCT-guided protocols help determine whether antibiotics are necessary, reducing their inappropriate use. Clinical trials and meta-analyses, including those reviewed by the , confirm that PCT-based algorithms safely reduce antibiotic duration by 2–4 days without increasing mortality or readmission rates [3].

Guidance in Neonatal and Pediatric Infections

In neonatal intensive care units, PCT plays a vital role in evaluating suspected early- or late-onset neonatal sepsis. Newborns may have physiologically elevated PCT levels in the first 24 hours of life (up to 20 ng/mL), but beyond this period, a level > 0.5 ng/mL raises concern for bacterial infection [26]. In older children, thresholds are similar to adults: < 0.2 ng/mL suggests low risk, while > 0.5 ng/mL indicates significant likelihood of bacterial infection [14]. This application is particularly important in pediatric emergency settings, where clinical signs can be nonspecific and blood cultures may take time to yield results.

Use in Postoperative and Trauma Settings

Following major surgery or severe trauma, PCT levels often rise transiently due to the systemic inflammatory response syndrome (SIRS), independent of infection. However, the kinetics of PCT are informative: levels typically peak at 24–48 hours postoperatively and then decline. A persistent or secondary rise beyond 72 hours is highly suggestive of postoperative infection, such as surgical site infection, pneumonia, or intra-abdominal abscess [5]. This dynamic monitoring enables earlier detection of complications and more targeted use of antibiotics, avoiding prolonged empiric regimens.

Role in Meningitis and Other Focal Infections

PCT also aids in the differential diagnosis of acute meningitis. When cerebrospinal fluid analysis is inconclusive, a serum PCT level > 1–2 ng/mL strongly favors bacterial meningitis over viral causes, where PCT remains low [29]. This helps guide decisions on continuing or discontinuing empiric antibiotics during diagnostic workups. Similarly, in febrile patients with indeterminate sources, PCT can help prioritize investigations and interventions based on the likelihood of bacterial dissemination.

Integration into Clinical Algorithms and Decision Support

PCT is most effective when integrated into validated clinical algorithms alongside , microbiological testing, and imaging. For example, the 2016 guidelines on PCT-guided antibiotic therapy in intensive care units (ICU) recommend initiating antibiotics if PCT > 0.5 µg/L and considering discontinuation when levels fall below 0.25 µg/L or decrease by more than 80% from peak values [30]. These protocols have been adopted in antimicrobial stewardship initiatives worldwide and are endorsed by organizations such as the , which recognizes PCT as an adjunct tool for de-escalating antibiotic therapy [9].

Despite its utility, PCT must never replace clinical judgment. Its interpretation requires contextualization within the full clinical picture, including patient comorbidities, immune status, and potential non-infectious causes of elevation. When used appropriately, PCT enhances diagnostic precision, optimizes , and supports a more personalized, evidence-based approach to infection management across diverse clinical environments.

Interpretation of PCT Levels and Thresholds

Procalcitonin (PCT) levels are interpreted using established clinical thresholds that guide the diagnosis, severity assessment, and management of bacterial infections. These thresholds are crucial for differentiating bacterial from viral etiologies, determining the need for antibiotic therapy, and monitoring treatment response. However, their application must always be contextualized within the patient’s full clinical picture, as PCT is a supportive biomarker rather than a standalone diagnostic tool.

Normal and Diagnostic Thresholds

In healthy individuals, PCT concentrations are typically very low, generally below 0.1 µg/L (or ng/mL) [32]. Some sources define a slightly higher upper limit of normal at 0.25 ng/mL, below which a severe bacterial infection is considered unlikely [4][6]. This baseline stability makes PCT a sensitive indicator of systemic bacterial inflammation, as levels rise rapidly in response to bacterial endotoxins and pro-inflammatory cytokines such as and .

Clinically useful thresholds include:

  • < 0.20 ng/mL: Highly suggests the absence of a systemic bacterial infection, with a strong negative predictive value [35].
  • 0.25–0.50 ng/mL: Indicates a possible localized or early bacterial infection, warranting close clinical monitoring and further evaluation [36].
  • > 0.50 ng/mL: Strongly suggestive of a systemic bacterial infection or sepsis, often justifying the initiation of [21].
  • > 2.0 ng/mL: Highly indicative of severe sepsis or septic shock, correlating with increased disease severity and mortality risk [30].

A threshold of ≥2 ng/mL is frequently used as a diagnostic criterion for bacteremia, offering high specificity [39], while a value below 0.2 ng/mL effectively rules out septicemia in most cases [40].

Clinical Application of Thresholds

The utility of PCT thresholds varies by clinical setting and patient population. In , a PCT level below 0.25 µg/L can help avoid unnecessary antibiotic initiation in patients with acute respiratory infections, particularly when a viral etiology is suspected [3]. Conversely, levels above this threshold support the need for interventions and targeted therapy.

In , PCT is integrated into evidence-based algorithms to guide antibiotic duration. According to the 2016 guidelines on PCT-guided antibiotic therapy in ICU, initiation is supported when PCT exceeds 0.5 µg/L, while discontinuation may be considered when levels fall below 0.25 µg/L or decrease by more than 80% from peak values, provided clinical improvement is observed [30].

In , thresholds are adapted for specific conditions:

  • For , a PCT > 0.25 ng/mL suggests bacterial involvement, whereas < 0.10 ng/mL makes bacterial infection highly improbable [24].
  • In exacerbations, a PCT > 0.25 ng/mL may justify antibiotic use, reducing overprescription [44].

Special Populations and Comorbidities

Thresholds must be adjusted in certain populations and clinical contexts. In neonates, PCT can be elevated at birth (up to 20 ng/mL), but beyond 24 hours, levels > 0.5 ng/mL raise concern for bacterial infection [26]. In pediatric patients, thresholds resemble those in adults, with < 0.20 ng/mL indicating low probability and > 2.0 ng/mL suggesting severe infection [14].

Comorbidities significantly influence PCT interpretation:

  • In , reduced clearance may lead to elevated PCT even without infection, necessitating higher thresholds (e.g., > 1.0 ng/mL) for diagnosing bacterial infection [47].
  • In , while baseline PCT may be altered, a marked elevation (> 2 ng/mL) remains suggestive of superimposed bacterial infection [48].

Limitations and Contextual Adjustments

Despite standardized thresholds, PCT interpretation must account for non-infectious conditions that can cause false positives, such as , , , , and certain [7]. In these settings, the kinetics of PCT—rather than a single value—are more informative. A transient rise followed by a decline suggests a sterile inflammatory response, while a secondary or persistent elevation signals possible infection [50].

Conversely, false negatives can occur in early infection, localized abscesses, or in immunocompromised patients, where the inflammatory response may be blunted [2]. Additionally, fungal infections like invasive candidiasis often do not elicit significant PCT elevation, limiting its sensitivity in such cases [52].

Therefore, PCT thresholds should be used as part of a multidimensional assessment that includes clinical signs, levels, , microbiological data, and imaging. International guidelines, including those from the , endorse PCT as an adjunct for antibiotic de-escalation but emphasize that it must never replace comprehensive clinical judgment [9].

Differentiation from Other Inflammatory Biomarkers

Procalcitonin (PCT) is distinguished from other inflammatory biomarkers by its superior specificity for systemic bacterial infections, particularly in differentiating bacterial sepsis from viral infections or non-infectious inflammatory conditions. Unlike general markers of inflammation such as or , PCT demonstrates a more targeted response to bacterial endotoxins and specific pro-inflammatory cytokines, making it a valuable tool in clinical decision-making [2].

Comparison with C-Reactive Protein (CRP)

The primary distinction between PCT and CRP lies in their origin and specificity. CRP is synthesized by the liver in response to , a cytokine released during any significant inflammatory stimulus, whether infectious or non-infectious [55]. Consequently, CRP levels rise in a wide range of conditions, including viral infections, autoimmune diseases, trauma, and post-surgical states, limiting its diagnostic precision for bacterial sepsis.

In contrast, PCT is induced primarily by bacterial endotoxins such as and cytokines like and , with IL-6 playing a secondary role [13]. This pathway is activated predominantly during systemic bacterial infections, resulting in high specificity. For example, PCT levels remain low in most viral infections, whereas CRP is typically elevated, making PCT a more reliable indicator for guiding antibiotic use in acute respiratory infections or suspected sepsis [3].

Additionally, the kinetic profiles differ: PCT rises earlier (within 3–4 hours) and peaks faster (12–24 hours) than CRP, which increases after 6–8 hours and peaks at 24–48 hours. This rapid onset allows for earlier clinical intervention. Furthermore, PCT has a longer half-life (22–29 hours) compared to CRP (19 hours), facilitating more stable monitoring over time [6].

Comparison with Interleukin-6 (IL-6)

IL-6 is a key pro-inflammatory cytokine and one of the earliest markers of immune activation. It is released rapidly—within 1–2 hours of an inflammatory stimulus—and peaks at 4–6 hours, making it highly sensitive for detecting early systemic inflammation [59]. However, its very short half-life (approximately 1 hour) and lack of specificity limit its clinical utility. IL-6 increases in response to virtually all forms of tissue injury, infection, or inflammation, including postoperative states and autoimmune flares.

While IL-6 can predict severity in sepsis and has been associated with mortality risk, its transient nature makes serial measurements logistically challenging and less practical for routine clinical use. In contrast, PCT, though slightly later in onset, persists longer and correlates more specifically with bacterial burden and disease severity. Studies suggest that while IL-6 dynamics may predict survival earlier than PCT, PCT remains more useful for guiding antibiotic duration due to its stability and stronger association with bacterial etiology [59].

Moreover, IL-6 assays are less standardized across laboratories, leading to greater inter-laboratory variability, whereas PCT is measured using widely available and reliable immunoassays, including and platforms [8].

Specificity in Clinical Contexts

PCT’s ability to distinguish bacterial from non-bacterial causes of inflammation is particularly advantageous in settings such as , , and . For instance, in patients with acute respiratory infections, a low PCT level (< 0.25 ng/mL) strongly suggests a viral or non-infectious origin, supporting the decision to withhold antibiotics. In contrast, CRP lacks this discriminatory power, often being elevated in both viral and bacterial cases [4].

However, PCT is not infallible. It can be elevated in certain non-infectious conditions such as major surgery, severe trauma, burns, and some cancers—particularly —which may mimic sepsis. Similarly, in conditions like severe pancreatitis or cardiogenic shock, PCT may rise due to systemic inflammatory response syndrome (SIRS) without infection [7]. Therefore, while PCT offers greater specificity than CRP or IL-6, it must still be interpreted within the full clinical context.

In summary, PCT stands out among inflammatory biomarkers due to its targeted induction by bacterial pathogens, rapid and sustained kinetics, and high specificity for systemic bacterial infection. These characteristics make it superior to CRP and IL-6 for differentiating bacterial from viral etiologies and for guiding antibiotic stewardship, especially in critical care environments [30].

Use in Antibiotic Stewardship and Treatment Guidance

Procalcitonin (PCT) has become a cornerstone in antimicrobial stewardship programs, serving as a key biomarker to guide both the initiation and duration of antibiotic therapy. Its primary value lies in reducing unnecessary antibiotic exposure, thereby mitigating the risk of , minimizing adverse drug effects, and lowering healthcare costs. By providing objective data on the likelihood of bacterial infection, PCT supports clinical decision-making in high-stakes environments such as the , , and inpatient medical wards [5]. International guidelines, including those from the , endorse PCT as an adjunct tool to de-escalate or discontinue antibiotics when clinical improvement is observed and PCT levels decline [9].

Guiding Antibiotic Initiation in Acute Respiratory Infections

In acute respiratory infections, such as community-acquired pneumonia (CAP) and acute exacerbations of chronic obstructive pulmonary disease (COPD), PCT is particularly effective in determining whether to start antibiotics. A PCT level below 0.25 ng/mL strongly suggests a non-bacterial etiology—often viral—and supports withholding antibiotic therapy [3]. This threshold has been validated in multiple randomized controlled trials and meta-analyses, including Cochrane reviews, which demonstrate that PCT-guided strategies reduce antibiotic use without increasing mortality or treatment failure rates [3]. For CAP, a PCT level above 0.25 ng/mL increases the likelihood of bacterial infection and justifies antibiotic initiation, while values exceeding 0.5 ng/mL are highly suggestive of severe bacterial involvement [24]. In COPD exacerbations, similar thresholds help distinguish infectious triggers from non-infectious causes, enabling more targeted use of and reducing overprescription [44].

Optimizing Duration of Antibiotic Therapy in Critical Care

In the ICU, PCT is widely used to guide the duration of antibiotic treatment, especially in patients with sepsis or septic shock. Serial PCT measurements allow clinicians to monitor the host response to therapy and assess whether the infection is resolving. According to evidence-based protocols, such as the 2016 guidelines on PCT-guided antibiotic therapy in ICU settings, antibiotics may be safely discontinued when PCT levels drop by more than 80% from their peak or fall below 0.5 ng/mL, provided the patient is clinically stable [30]. This approach has been shown to shorten antibiotic courses by 2 to 4 days on average, significantly reducing cumulative exposure [3]. In septic patients, a failure of PCT to decline—or a secondary rise—can signal inadequate source control, resistant pathogens, or superimposed infections, prompting re-evaluation of the treatment plan [73]. The integration of PCT into ICU protocols thus enhances the precision of and supports de-escalation strategies.

Role in Postoperative and Surgical Infections

Following major surgery, including cardiac, abdominal, or trauma-related procedures, PCT levels often rise transiently due to the systemic inflammatory response, even in the absence of infection. However, the kinetics of PCT are highly informative: levels typically peak within 24–48 hours and then decline rapidly if no infection develops. A persistent or secondary increase beyond this period is a red flag for postoperative infection, such as surgical site infection, pneumonia, or intra-abdominal abscess [14]. PCT-guided algorithms in surgical settings recommend delaying or discontinuing antibiotics when PCT decreases appropriately, helping to avoid prolonged prophylactic or empirical regimens. For instance, in patients undergoing cardiothoracic surgery with extracorporeal circulation, a rising or plateaued PCT after 72 hours warrants investigation for infectious complications [75]. This dynamic monitoring enhances the ability to differentiate between sterile inflammation and true infection, thereby optimizing antibiotic use in surgical populations.

Application in Meningitis and Neonatal Infections

PCT also plays a valuable role in diagnosing bacterial meningitis and managing infections in neonates. In acute meningitis, a PCT level above 1–2 ng/mL strongly favors a bacterial etiology over viral causes, where PCT typically remains low [29]. This distinction is crucial when cerebrospinal fluid analysis is inconclusive or when rapid decisions are needed in epidemic settings. In neonatal care, PCT is used to assess the risk of early- or late-onset bacterial infection. Although PCT can be elevated at birth (up to 20 ng/mL in the first 24 hours), levels should decline rapidly; a PCT above 0.5 ng/mL beyond the first day raises concern for sepsis and may justify starting antibiotics [26]. Conversely, a falling PCT trend supports early discontinuation of antibiotics in well-appearing infants with negative cultures, reducing unnecessary exposure in a vulnerable population [78].

Integration into Clinical Algorithms and Decision Support

The effectiveness of PCT in antibiotic stewardship is maximized when it is embedded within structured clinical algorithms that combine biomarker data with clinical assessment, microbiological results, and imaging findings. These multidimensional approaches prevent overreliance on PCT alone and reduce the risk of misinterpretation in complex cases. For example, in CAP, protocols recommend repeating PCT every 2–3 days to assess response, with discontinuation considered when levels fall below 0.25 ng/mL or decrease by over 80% from peak [5]. Electronic health record systems can be programmed to generate alerts based on PCT trends, supporting timely interventions by and . Such integration ensures that PCT serves as a decision-support tool rather than a standalone diagnostic, aligning with principles of evidence-based medicine and enhancing patient safety in antibiotic prescribing.

Limitations and Non-Infectious Causes of Elevation

Procalcitonin (PCT) is widely recognized for its high specificity in detecting systemic bacterial infections, particularly sepsis, and for guiding antibiotic stewardship in clinical settings such as and . However, its utility is constrained by several limitations, most notably the potential for elevated levels in the absence of bacterial infection. These non-infectious causes of PCT elevation can lead to false-positive interpretations, potentially resulting in unnecessary antibiotic use. Therefore, accurate clinical interpretation requires careful integration of PCT results with the patient’s full clinical picture, comorbidities, and other diagnostic data [7].

Non-Infectious Conditions Associated with Elevated Procalcitonin

Several non-infectious conditions can induce significant increases in PCT levels, mimicking bacterial sepsis and complicating diagnosis. These include:

  • Major trauma and polytrauma: Severe physical injuries trigger a systemic inflammatory response syndrome (SIRS), leading to PCT elevation independent of infection. This increase typically peaks within 24–48 hours post-injury and correlates with injury severity scores such as the Injury Severity Score (ISS) [81]. A transient rise is expected, but persistent or secondary elevation beyond 72 hours should raise suspicion for infection.

  • Extensive burns: Patients with large burn surface areas often exhibit markedly elevated PCT levels due to massive tissue damage and cytokine release. While initial elevation is common, a failure of PCT to decline or a secondary rise may indicate superinfection or sepsis [82].

  • Major surgery and postoperative states: Following major surgical procedures—especially cardiac surgery with cardiopulmonary bypass—PCT levels commonly rise within 6–24 hours, peaking at 24–48 hours. This reflects the surgical stress response rather than infection. In uncomplicated recoveries, PCT levels normalize within 3–5 days [6]. Prolonged elevation suggests possible complications such as surgical site infections or anastomotic leaks.

  • Shock states (non-septic): Both cardiogenic and hypovolemic shock can cause substantial PCT elevation due to tissue hypoperfusion and the release of pro-inflammatory mediators. This limits the ability to differentiate septic from non-septic shock based on PCT alone [7].

  • Severe pancreatitis: Acute necrotizing pancreatitis, even in the absence of bacterial infection, can lead to high PCT levels. While values >2 ng/mL are associated with an increased risk of infected necrosis, PCT cannot reliably distinguish sterile from infected necrosis without microbiological confirmation [85].

  • Inhalation injury and acute lung injury: Non-infectious pulmonary inflammation, such as that caused by smoke inhalation or acute respiratory distress syndrome (ARDS), may also elevate PCT levels, complicating the diagnosis of ventilator-associated pneumonia [7].

Neoplastic and Autoimmune Causes

Certain malignancies and autoimmune disorders are also associated with elevated PCT:

  • Neuroendocrine tumors: Tumors such as medullary thyroid carcinoma and other neuroendocrine neoplasms can produce PCT ectopically, leading to chronically elevated levels unrelated to infection [87]. Hepatic neuroendocrine tumors, whether primary or metastatic, have also been linked to high PCT concentrations [88].

  • Autoimmune and inflammatory diseases: Conditions like adult-onset Still’s disease, severe rheumatoid arthritis, and other connective tissue disorders can present with elevated PCT, sometimes mimicking sepsis. In these cases, concurrent markers such as ferritin and or may help differentiate inflammatory from infectious etiologies [89].

  • Drug reactions: Severe immune-mediated reactions such as DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) can trigger PCT elevation, further complicating differential diagnosis in febrile patients [90].

Organ Dysfunction and Metabolic Stress

Organ failure and metabolic disturbances can also influence PCT levels:

  • Renal insufficiency: While PCT is primarily cleared renally, its half-life is not significantly prolonged in renal failure. However, patients with chronic kidney disease or on hemodialysis may exhibit moderately elevated baseline PCT levels, necessitating higher diagnostic thresholds (e.g., >1.0 ng/mL) to suspect infection [47].

  • Hepatic failure: Severe liver dysfunction may alter PCT metabolism and clearance, potentially affecting its levels. Nevertheless, marked elevations (>2 ng/mL) in this context still raise concern for superimposed bacterial infection [48].

  • Acute heart failure: In decompensated heart failure, particularly with low cardiac output, PCT can rise due to systemic inflammation and gut translocation of bacterial products, even without active infection [93].

Interpretation Challenges and Clinical Strategy

To avoid misdiagnosis and inappropriate antibiotic use, clinicians must interpret PCT within a multidimensional framework. Key strategies include:

  • Assessing PCT kinetics: The trend over time is often more informative than a single value. A declining PCT curve in a clinically improving patient supports a non-infectious or resolving infectious process, whereas a rising or plateauing level warrants investigation for occult infection [21].

  • Integrating clinical and laboratory data: Combining PCT with other biomarkers such as , , white blood cell count, and microbiological results enhances diagnostic accuracy. For instance, discordance between rising CRP and falling PCT may suggest non-infectious inflammation [95].

  • Using validated algorithms: Decision-support tools that incorporate PCT thresholds—such as initiating antibiotics if PCT >0.5 ng/mL and considering discontinuation if PCT drops by >80% from peak or falls below 0.25–0.5 ng/mL—have been shown to safely reduce antibiotic duration [3].

  • Avoiding isolated reliance on PCT: The emphasizes that PCT should never replace clinical judgment and should be used as an adjunct, not a standalone test [9].

In summary, while PCT is a valuable tool in infection management, its elevation in non-infectious conditions necessitates cautious interpretation. Clinicians must remain vigilant for false positives and employ a holistic, evidence-based approach to ensure optimal patient outcomes and effective .

Monitoring Response and Prognostic Value in Critical Care

Procalcitonin (PCT) serves as a critical tool in the intensive care unit (ICU) for monitoring patient response to therapy and assessing prognosis, particularly in cases of severe bacterial infection and sepsis. Its dynamic nature allows clinicians to track the trajectory of infection and inflammation over time, providing insights beyond static clinical signs. The value of PCT lies not only in its initial elevation but in its kinetics—the pattern of rise and fall—which correlates strongly with clinical outcomes and therapeutic efficacy [7]. A rapid decline in PCT levels following antibiotic initiation is associated with improved survival and reduced risk of complications, making it a powerful prognostic indicator in critical illness.

Prognostic Significance in Sepsis and Septic Shock

In patients with sepsis or septic shock, baseline PCT levels and their subsequent trends offer significant prognostic information. Elevated PCT concentrations, particularly those exceeding 2.0 µg/L, are strongly associated with increased disease severity, higher risk of organ dysfunction, and greater mortality [99]. A threshold of 32.5 µg/L has been linked to a 96% specificity for predicting 30-day mortality, underscoring its utility in risk stratification [99]. Serial measurements enhance this predictive power: a reduction of 50–80% in PCT levels within 72 hours of starting antibiotics is a robust marker of favorable response and correlates with lower hospital mortality [73]. Conversely, persistent or rising PCT levels suggest inadequate source control, ineffective antimicrobial therapy, or the development of secondary complications such as superinfection, prompting urgent re-evaluation of the clinical management plan [17]. This makes PCT an essential component of the sepsis workup, guiding not only treatment duration but also the intensity of monitoring required.

Guiding Antibiotic Duration Through Kinetic Monitoring

One of the most impactful applications of PCT in critical care is its role in optimizing antibiotic stewardship through kinetic monitoring. Clinical algorithms based on PCT trends enable clinicians to safely shorten the duration of antibiotic therapy, reducing the risk of antimicrobial resistance and drug-related adverse effects. Guidelines such as the PCT-Guided Antibiotic Therapy in ICU 2016 recommend initiating antibiotics when PCT exceeds 0.5 µg/L in the context of suspected severe infection [30]. The decision to discontinue antibiotics is supported by a PCT level below 0.25 µg/L or a decrease of more than 80% from the peak value, provided the patient is clinically improving [5]. This approach has been validated in randomized trials and meta-analyses, including those by the Cochrane Collaboration, which confirm that PCT-guided protocols reduce antibiotic exposure by 20–40% without increasing morbidity or mortality [3]. The integration of PCT into antimicrobial stewardship programs is thus a cornerstone of modern critical care practice.

Utility in Postoperative and Trauma Settings

In postoperative and trauma patients, the interpretation of PCT must account for non-infectious systemic inflammatory responses. Following major surgery, particularly cardiac procedures involving cardiopulmonary bypass, PCT typically rises within 24–48 hours, peaking at moderate levels (up to 2–5 ng/mL) before declining [106]. A transient elevation in this context reflects surgical stress rather than infection. However, the kinetic profile becomes crucial: a failure of PCT to decline or a secondary rise beyond 72 hours is highly suggestive of postoperative infection, such as surgical site infection, pneumonia, or intra-abdominal abscess [50]. Similarly, in polytrauma or severe burns, early PCT elevation is common due to tissue damage and shock, but persistent levels warrant investigation for sepsis [81]. Thus, while initial values may be misleading, serial PCT measurements provide a reliable means to differentiate sterile inflammation from true infection, guiding timely intervention when needed.

Integration with Multidimensional Clinical Algorithms

The prognostic and therapeutic value of PCT is maximized when it is integrated into multidimensional decision-making frameworks. It should never be used in isolation but rather combined with clinical assessment, microbiological data, imaging, and other biomarkers such as C-reactive protein (CRP) and lactate. For instance, while CRP reflects general inflammation with a slower turnover, PCT offers greater specificity for bacterial sepsis and faster clearance, allowing for more responsive treatment adjustments [6]. Discrepancies between PCT and CRP trends can provide additional diagnostic clarity. Moreover, in patients with acute respiratory distress syndrome (ARDS) or multiple organ dysfunction syndrome (MODS), PCT kinetics help assess whether ongoing organ failure is driven by uncontrolled infection or other pathophysiological processes. The use of PCT within structured protocols endorsed by organizations like the Surviving Sepsis Campaign ensures that its application is evidence-based and clinically meaningful [9].

Analytical Methods and Measurement Challenges

The accurate quantification of procalcitonin (PCT) is essential for its clinical utility in diagnosing bacterial infections and guiding antibiotic therapy. Modern measurement techniques primarily rely on automated immunometric assays, including chemiluminescence, immunofluorescence, and enzyme-linked immunosorbent assays (ELISA) [8]. These methods are widely implemented in central laboratory analyzers and are also available in point-of-care testing (POCT) formats, allowing for rapid turnaround times—often under 30 minutes—which is particularly valuable in emergency medicine and intensive care units (ICU) settings [8]. The performance of major commercial systems from manufacturers such as Roche, Beckman Coulter, Thermo Fisher Scientific, and Siemens Healthineers has been rigorously evaluated, with most demonstrating high sensitivity and precision [113].

Typical analytical performance metrics for these assays include a limit of detection (LoD) below 0.02 µg/L and a limit of quantification (LoQ) around 0.05 µg/L, ensuring reliable measurement even at low concentrations. Intra- and inter-assay coefficients of variation (CV) are generally less than 10%, reflecting good reproducibility across different runs and laboratories [113]. However, despite these favorable characteristics, significant challenges remain, particularly concerning standardization and inter-method variability. Studies have demonstrated moderate but clinically relevant discrepancies in PCT results when comparing different assay platforms, which can affect the comparability of values across laboratories and potentially impact clinical decision-making [115]. This lack of harmonization is a major obstacle to the universal application of established clinical thresholds.

To address this issue, international efforts led by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Working Group on Procalcitonin (WG-PCT) are underway to develop a reference measurement procedure. This initiative aims to establish metrological traceability using liquid chromatography-tandem mass spectrometry (LC-MS/MS), a technique capable of absolute quantification independent of antibody-based detection [116]. The development of such a reference method is critical for improving the accuracy and comparability of PCT measurements globally, thereby enhancing the reliability of clinical guidelines that rely on specific concentration thresholds [117].

Sources of Analytical Interference and Preanalytical Variability

Several factors can compromise the accuracy of PCT measurement, necessitating careful interpretation, especially when clinical and laboratory findings are discordant. One of the most well-documented sources of interference is the presence of heterophilic antibodies—endogenous antibodies that can bind to assay antibodies in sandwich immunoassays, leading to falsely elevated or depressed results [118]. Patients exposed to animals, certain vaccines, or monoclonal antibody therapies are at higher risk. Mitigation strategies include the use of blocking agents in reagents, testing after sample dilution (where non-linear results suggest interference), or employing alternative assay platforms with different antibody pairs [119].

Preanalytical factors also play a crucial role in result reliability. The type of sample is important; serum is generally preferred over plasma, as certain anticoagulants may interfere with the assay. The time to centrifugation should ideally be within two hours of blood collection to prevent cellular degradation and analyte instability. PCT is relatively stable in serum, with acceptable stability for up to 24 hours at room temperature, 7 days at 4°C, and several months when stored at -70°C for biobanking purposes [120]. However, sample mishandling, such as hemolysis or contamination, can still affect assay performance.

Furthermore, the lack of commutable control materials—reference samples that behave identically across different assay methods—complicates external quality assessment programs. Non-commutability means that quality control materials may not accurately reflect the performance of an assay with real patient samples, potentially leading to misleading performance evaluations [121]. Laboratories must therefore implement robust validation protocols, participate in external quality assurance schemes, and establish procedures for detecting and resolving interferences to ensure the integrity of PCT testing [116].

Special Populations and Contextual Considerations

The interpretation of procalcitonin (PCT) levels requires careful contextualization, particularly in special patient populations and clinical scenarios where baseline physiology, comorbidities, or non-infectious inflammatory states can significantly influence PCT concentrations. While PCT is a valuable biomarker for bacterial infection, its utility must be balanced against the risk of misinterpretation in vulnerable or complex patients. Clinicians must integrate PCT results with a comprehensive assessment of the patient’s condition to avoid inappropriate antibiotic use or delayed diagnosis.

Neonatal and Pediatric Populations

In neonates, PCT interpretation is complicated by physiological fluctuations during the first days of life. PCT levels can be transiently elevated at birth, reaching up to 20 ng/mL in the first 24 hours, due to perinatal stress and activation of the immune system [26]. However, PCT typically declines rapidly thereafter, and a level above 0.5 ng/mL beyond the first day should raise suspicion for early-onset or late-onset bacterial infection, such as sepsis or meningitis. This makes PCT a useful tool in guiding the initiation or discontinuation of antibiotic therapy in this vulnerable population, where clinical signs of infection may be subtle or nonspecific [124].

In older children, PCT thresholds resemble those in adults: levels below 0.20 ng/mL suggest a low likelihood of bacterial infection, while values above 0.5 ng/mL indicate a significant risk of severe bacterial disease, and levels exceeding 2.0 ng/mL are highly suggestive of sepsis [14]. PCT is particularly helpful in pediatric emergency settings for differentiating bacterial from viral respiratory infections, thereby supporting antimicrobial stewardship. However, its use should be targeted and interpreted alongside clinical findings, as indiscriminate testing may lead to misdiagnosis or unnecessary treatment [126].

Patients with Renal or Hepatic Impairment

Renal dysfunction can affect PCT levels, as the biomarker is primarily cleared via the kidneys. In patients with chronic or acute kidney injury, including those on hemodialysis, PCT may accumulate even in the absence of infection, leading to potential overestimation of bacterial disease severity [47]. Therefore, higher thresholds—such as a PCT > 1.0 ng/mL—may be more appropriate to confirm infection in this population and avoid false-positive interpretations. Despite this, marked elevations (e.g., > 2 ng/mL) remain clinically significant and should prompt thorough evaluation for sepsis.

In contrast, severe liver disease, such as cirrhosis or acute hepatic failure, may impair the production of PCT, potentially blunting its rise during bacterial infection [48]. This reduced sensitivity complicates diagnosis, as a normal or only mildly elevated PCT does not reliably exclude sepsis in patients with advanced liver disease. In such cases, clinicians must rely more heavily on clinical judgment, microbiological data, and other markers of systemic inflammation, such as levels or the .

Postoperative, Trauma, and Burn Patients

In the immediate postoperative period, major surgery—especially procedures involving cardiopulmonary bypass or extensive tissue manipulation—can trigger a systemic inflammatory response that elevates PCT independently of infection. PCT typically peaks within 24 to 48 hours after surgery and then declines rapidly if no complications arise [7]. A persistently high or rising PCT beyond this window, however, is strongly suggestive of a postoperative infection, such as surgical site infection, pneumonia, or intra-abdominal abscess [5].

Similarly, patients with severe trauma or extensive burns often exhibit elevated PCT due to massive tissue injury and the resulting release of pro-inflammatory mediators. In these cases, PCT lacks specificity for infection during the acute phase. However, its kinetic profile becomes informative: a secondary rise or failure to decline after an initial peak may indicate the development of sepsis or wound infection [81]. Thus, serial monitoring of PCT is more valuable than a single measurement in guiding antimicrobial decisions in trauma and burn units.

Immunocompromised and Critically Ill Patients

In immunocompromised individuals—including those with neutropenia, organ transplantation, or on immunosuppressive therapy such as —the inflammatory response to infection may be attenuated, leading to lower-than-expected PCT levels despite severe bacterial disease [132]. This reduced sensitivity increases the risk of false-negative results, necessitating a low threshold for initiating antibiotics based on clinical suspicion rather than PCT alone.

Conversely, certain conditions can cause false-positive elevations. For example, patients with severe non-infectious systemic inflammation—such as , , or autoimmune diseases like adult-onset Still’s disease—may exhibit high PCT levels mimicking sepsis [93]. Additionally, some cancers, particularly neuroendocrine tumors such as medullary thyroid carcinoma or hepatic neuroendocrine metastases, can produce PCT ectopically, leading to chronically elevated levels unrelated to infection [87].

Infections with Atypical or Fungal Pathogens

PCT has limited utility in diagnosing infections caused by non-bacterial pathogens. While it remains low in most viral infections—making it useful for distinguishing viral from bacterial etiologies—certain severe viral illnesses, including advanced , may be associated with elevated PCT, potentially due to secondary bacterial invasion or intense systemic inflammation [135]. More importantly, invasive fungal infections such as candidemia or aspergillosis typically do not elicit a strong PCT response, resulting in low or only moderately elevated levels [52]. Therefore, a low PCT should not be used to rule out fungal sepsis, especially in high-risk patients, and should prompt the use of other diagnostic tools such as or assays.

In summary, while PCT is a powerful adjunct in infection management, its application in special populations demands nuanced interpretation. Factors such as age, organ function, immune status, and non-infectious inflammatory conditions must be considered to prevent diagnostic errors. Integration of PCT into multidimensional clinical algorithms—combining , , imaging, and other like and —ensures its optimal and safe use across diverse patient groups [137].

Integration into Clinical Algorithms and Guidelines

Procalcitonin (PCT) has been systematically integrated into clinical algorithms and guidelines across multiple medical specialties to optimize the diagnosis, management, and duration of antimicrobial therapy, particularly in critical care, emergency medicine, and respiratory diseases. Its role is primarily adjunctive, designed to support clinical judgment rather than replace it, and is endorsed by major international organizations such as the and various national infectious disease societies [9]. These guidelines emphasize the use of PCT in structured protocols that combine serial measurements with clinical assessment, aiming to reduce unnecessary antibiotic exposure and combat the growing threat of .

Use in Sepsis and Critical Care Protocols

In the management of sepsis and septic shock, PCT is incorporated into evidence-based algorithms to guide both the initiation and discontinuation of antibiotics. The 2016 guidelines on PCT-guided antibiotic therapy in the intensive care unit (ICU) recommend initiating antibiotics when PCT levels exceed 0.5 µg/L in the context of suspected infection, reflecting a high probability of bacterial etiology [30]. Conversely, antibiotic cessation is strongly considered when PCT decreases by more than 80% from its peak value or falls below 0.5 µg/L, provided the patient is clinically stable [30]. This approach has been validated in randomized trials such as the BU-37 and Pro-Can studies, which demonstrated that PCT-guided protocols safely reduce antibiotic duration by 2 to 4 days without increasing mortality or readmission rates [141][142]. The acknowledges PCT as a supportive tool for de-escalating therapy, although it notes the strength of recommendation is low due to heterogeneity in patient populations and assay variability [143].

Application in Respiratory Infections and Pneumonia

PCT is widely recommended in guidelines for managing acute respiratory infections, including community-acquired pneumonia (CAP) and exacerbations of chronic obstructive pulmonary disease (COPD). In CAP, a PCT level below 0.1 µg/L indicates a very low likelihood of bacterial infection and supports withholding antibiotics, while levels above 0.25 µg/L suggest bacterial involvement and justify antibiotic therapy [24]. For antibiotic discontinuation, a reduction to less than 0.25 µg/L or an 80% drop from peak levels is used as a stopping criterion [5]. A Cochrane review confirms that PCT-guided strategies reduce antibiotic duration in acute respiratory infections by 2 to 4 days without compromising clinical outcomes, reinforcing its integration into stewardship programs [3]. In COPD exacerbations, similar thresholds are applied to avoid overprescription, particularly in mild to moderate cases where viral etiologies are common [44].

Role in Postoperative and Trauma Care

In postoperative settings, PCT is used to differentiate between systemic inflammatory response syndrome (SIRS) and surgical site infections or sepsis. After major surgery, PCT typically peaks within 24 to 48 hours and then declines rapidly in the absence of infection. A persistent or secondary rise in PCT beyond 72 hours is highly suggestive of a bacterial complication, such as peritonitis or pneumonia, and prompts further investigation and potential antibiotic initiation [148]. Conversely, a declining trend supports the safety of discontinuing prophylactic antibiotics. In severe trauma and burns, early PCT elevation is common due to tissue injury and is not diagnostic of infection. However, serial monitoring is valuable: a failure of PCT to decrease or a secondary increase alerts clinicians to possible sepsis, guiding timely intervention [81]. Algorithms in this context integrate PCT with clinical signs, imaging, and microbiological data to avoid both under- and over-treatment [5].

Pediatric and Neonatal Considerations

In pediatrics and neonatology, PCT algorithms are adapted to age-specific physiological variations. In newborns, PCT can be elevated at birth (up to 20 ng/mL) but normally declines within 24 to 48 hours. A level above 0.5 ng/mL beyond this period raises suspicion for early-onset sepsis [26]. In older children, thresholds resemble those in adults: values below 0.2 ng/mL make bacterial infection unlikely, while levels above 2.0 ng/mL strongly suggest sepsis [14]. PCT is particularly useful in pediatric emergency departments to distinguish bacterial from viral meningitis, where levels above 1–2 ng/mL are highly suggestive of bacterial etiology, allowing for targeted use of intravenous antibiotics [29]. However, guidelines stress that PCT must be interpreted alongside clinical findings, cerebrospinal fluid analysis, and other biomarkers like to avoid misdiagnosis [154].

Multidimensional Decision-Making and Stewardship Programs

The most effective use of PCT occurs within multidimensional decision-making frameworks that combine clinical assessment, microbiological testing, and other biomarkers. In antimicrobial stewardship programs, PCT is embedded in institutional protocols that include automated alerts, order sets, and pharmacist-led reviews to ensure appropriate test utilization and interpretation [155]. These programs have been shown to reduce antibiotic use by 20–40% without increasing adverse outcomes [3]. However, barriers to optimal implementation include lack of standardized national guidelines, variable clinician adherence, and misinterpretation of results, particularly in non-infectious inflammatory states [157]. Successful integration requires ongoing education, local protocol development, and collaboration between , intensivists, microbiologists, and pharmacists to ensure PCT is used within its validated indications and not as a standalone diagnostic test [30].

References